



Childhood cardiomyopathies

Damien Bonnet

Unité médico-chirurgicale de Cardiologie Congénitale et Pédiatrique
Hôpital Universitaire Necker Enfants malades – APHP, Université Paris Descartes, Sorbonne Paris Cité
IcarP Cardiology, Institut Hospitalo-Universitaire IMAGINE


Centre de Référence Maladies Rares
Malformations Cardiaques Congénitales Complexes-M3C
Centre de Référence Maladies Rares
Maladies Cardiaques Héritaires- CARDIOGEN




Epidemiology

- Annual incidence of childhood cardiomyopathies : 1.13 per 100,000
- Incidence higher among children <1 year :
8.34 vs. 0.70 per 100,000
- Categorized according to type :
 - Hypertrophic 42 %
 - Dilated 51%
 - Restrictive 2.5%
 - Non compaction 9.2%
- Sudden death as presenting symptom 3.5%


Cumulative frequency distribution of age at presentation



Survival to death or transplantation from time to presentation in pediatric cardiomyopathies



No. at risk	175	128	103	92	77	60	48	37	28	15	8
-------------	-----	-----	-----	----	----	----	----	----	----	----	---




No. at risk											
0-4wks	34	22	17	11	10	10	9	7	4	2	2
>4wks-1yr	78	68	52	48	39	27	22	18	12	7	4
>1yr-5yrs	47	40	35	32	25	21	18	13	9	5	1
>5yrs	16	6	4	3	3	2	1	1	1	1	1


Daubeney PEF et al. Circulation 2006
Alexander PMA et al. Circulation 2013

Wittlieb-Weber CA et al. J Card Failure 2015;21:76-82
Rossano JW et al. J Card Fail 2012;18:459-70.

Survival to death or transplantation from time to presentation in pediatric cardiomyopathies





No. at risk		0	1	2	3	4	5	6	7	8	9	10
No	149	114	98	83	68	52	41	32	22	12	6	
Yes	28	12	10	9	9	8	7	5	4	3	2	




No. at risk		0	1	2	3	4	5	6	7	8	9	10
No	26	20	17	14	13	10	9	8	5	2	1	
Yes	13	13	13	12	11	8	4	3	2	2	1	

Hemodynamic in normal heart - Bottlenecks






Left ventricular failure
Pulmonary hypertension




Right ventricular failure - Preload of LV reduced


Pressure-Volume loop



Dilated cardiomyopathy with poor contractility




Restrictive cardiomyopathy with poor compliance



Systolic dysfunction


Low contractility/treatment




Phenotypes of cardiomyopathies

Cardiac phenotypes


Dilated





Hypertrophic




Arrhythmogenic





Dilated cardiomyopathy




Hypertrophic cardiomyopathy






Restrictive cardiomyopathy





Non compaction



Ischemic cardiomyopathy





Left ventricular aneurysm



Right ventricular cardiomyopathies



A.R.V.D




Difficulties in phenotyping

- Unusual phenotypes
 - Dilated with hypertrophic walls and restrictive physiology
- Changing phenotype
 - From hypertrophic to dilated
- Uncertain phenotype
 - Penetrance increasing with age

Cardiomyopathies are rarely familial and a known cause of ventricular dilatation and/or hypertrophy should be extensively searched

- Tako-tsubo
- Volume and pressure overload
- Myocardial ischemia
- Sustained arrhythmias
- Infective myocarditis
- Toxic
- Neuromuscular disorders
- Syndromic cardiomyopathies
- Metabolic diseases


Purely environmental cardiomyopathy ?




Takotsubo

Heart failure due to increased afterload

Normal contractility and compliance




Critical aortic valve stenosis




Heart failure due to increased preload

Normal contractility and compliance



Severe mitral valve regurgitation






Ischemic cardiomyopathies





ALCAPA-Main stem atresia
Post-operative
TGA
Kawasaki disease
Hypercholesterolemia
GACI

GACI




Arrhythmic cardiomyopathy

- Supraventricular tachycardia of the newborn
- Booby-traps
 - Atrial arrhythmias after atrial correction of TGA
 - Arrhythmias after TCPC



Arrhythmic cardiomyopathy fetal

JT/AVB



Infectious cardiomyopathies

Viral myocarditis

Lyme disease


Chagas disease

HIV


Toxoplasmosis


Rheumatic

Myocarditis in children



Myocarditis





Time to recovery of left ventricular function in CMR-positive group (full line) and in the CMR-negative group (dotted line) with 95% CI (grey dotted lines).

Toxic

- Anthracyclines
- Radiations

Neuromuscular disorders

- Dystrophinopathies
 - Duchenne de Boulogne
 - Becker
- Emery-Dreyfus
- Laminopathies
- Steinert
- Friedreich




First stop !

What have you done ?

- Clinical examination
- Medical history
- ECG
- Echocardiography
- Troponine
- MRI


Malformation syndromes and cardiomyopathies





RASopathies

Inborn errors of metabolism and cardiomyopathies



Cardiac involvement in IEM

- Cardiomyopathies
 - Storage diseases
 - Systolic dysfunction in energetic defects & intoxications
 - Phenotypic variability and atypical evolution of RC defects
- Arrhythmias
 - Triggered and automatic activities in intoxications
 - Facilitated conduction and accessory pathways in glycogenoses
 - Atypical AV blocks
- Valvular thickening in mucopolysaccharidoses
- Pericardial effusion in glycosylation defects
- Congenital heart defects¹?

1-Romano S. et al. J Med Genet 2009.

Conotruncal heart defects in three patients with congenital disorder of glycosylation type Ia (CDG Ia)

When should you think of metabolic cardiomyopathy ?

- Family history of sudden death or unexplained death in infancy
- Multisystemic disease
- Changing phenotype
- Severe hemodynamic compromise with mild alteration of LV function
- Atypical anomalies of ECG : left bundle branch bloc, AVB, ventricular tachycardia

Cardiac metabolism for pediatric cardiologists

Substrate accumulation (non toxic):
storage diseases

Lysosomal : HCM, valves
Peroxisomal
Reticulum: glycosylation

Substrate

Metabolism


Product

Organic
aciduria

Fatty-acid oxydation
Respiratory chain
Krebs cycle
Glycogenoses


Substrate accumulation (toxic):
intoxication diseases

Product decrease or absent :
energetic defects



Pompe's disease

Fatty acid oxidation



Presenting symptoms of FAO disorders

Neonatal neurological distress 23%

Hypoglycemia Hypoketotic 46%

Reye 's syndrome 30%

Arrhythmias 14%

Cardiomyopathies 12%

Sudden death 7%

Near-miss 7%

Myolysis, myoglobinuria 6%


Muscular weakness 2%

Hepatomegaly 2%


Cholestasis 1%




Carnitine deficiency



Mitochondrial disease



Genetic screening for HCM in adults



- **Inborn errors of metabolism**
 - Glycogen storage diseases:
 - Pompe
 - Danon
 - AMP-Kinase (PRKAG2)
 - Carnitine disorders
 - Lysosomal storage diseases
 - Anderson-Fabry
- **Neuromuscular diseases**
 - Friedreich's ataxia
 - FHLI
- **Mitochondrial diseases**
 - MELAS
 - MERFF
- **Malformation Syndromes**
 - Noonan
 - LEOPARD
 - Costello
 - CFC
- **Amyloidosis**
 - Familial ATTR
 - Wild type TTR (senile)
 - AL amyloidosis

Familial screening

- First degree relatives
- ECG
- Echocardiography
- Genetic testing according to local practice and legal recommendations for presymptomatic screening

Summary of clinical evaluation and etiology search for cardiomyopathies

- Medical history personal and familial
- Cardiac examination
- ECG + Echocardiography
- MRI + troponin
- Genetic clinic for syndromes
- Metabolic screening
 - Glucose, ketone bodies, lactates,
 - Chromato organic acids, acylcarnitines, carnitine T+F

 - and that's it!

